Wang Chongkai, Sandhu Jaideep, Tsao Amber, Fakih Marwan
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Cancers (Basel). 2022 Jul 27;14(15):3644. doi: 10.3390/cancers14153644.
Prior studies have resulted in conflicting conclusions on the value of mutations as a prognostic biomarker in metastatic colorectal cancer. In this study, the impact of coexisting mutations with on overall survival was evaluated retrospectively in 433 patients with metastatic colorectal cancer. mutation was found in 16.2% (70/433) of tumors. A systemic univariate and multivariate survival analysis model including age, gender, sidedness of primary tumor, , , , and status showed that mutations were not associated with worse prognosis (multivariate HR = 1.25, 95% CI 0.90-1.73, = 0.18). However, coexisting mutations in and were significantly associated with worse overall survival (multivariate HR = 2.5, 95% CI 1.44-4.36, = 0.001). The median overall survival of patients with coexisting and mutation was 24.2 months, compared to 42.2 months for the rest of the population ( = 0.002). Concurrent and defines a new subgroup of patients of metastatic colorectal cancer with poor clinical outcomes.
先前的研究对于突变作为转移性结直肠癌预后生物标志物的价值得出了相互矛盾的结论。在本研究中，对433例转移性结直肠癌患者的共存突变对总生存期的影响进行了回顾性评估。在16.2%（70/433）的肿瘤中发现了 突变。一个包括年龄、性别、原发肿瘤部位、 、 、 、 和 状态的单变量和多变量生存分析模型显示， 突变与较差的预后无关（多变量风险比=1.25，95%置信区间0.90-1.73， =0.18）。然而， 和 的共存突变与较差的总生存期显著相关（多变量风险比=2.5，95%置信区间1.44-4.36， =0.001）。共存 和 突变患者的中位总生存期为24.2个月，而其余人群为42.2个月（ =0.002）。 和 的同时存在定义了一组临床结局较差的转移性结直肠癌新亚组患者。
